A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous Medication (REVIVE)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
H. Lundbeck A/S
ClinicalTrials.gov Identifier:
NCT01488071
First received: November 29, 2011
Last updated: February 11, 2014
Last verified: February 2014
Results First Received: December 19, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Treatment
Condition: Major Depressive Disorder
Interventions: Drug: Vortioxetine (Lu AA21004)
Drug: Agomelatine

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
In- or outpatients who had been treated with antidepressant selective serotonin reuptake inhibitor (SSRI) or selective noradrenaline reuptake inhibitor (SNRI) monotherapy that was prescribed to treat a single episode of Major Depressive Disorder (MDD) or recurrent MDD.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
The study will consist of a screening period of 4 to 10 days before the Baseline Visit, followed by a 12-week treatment period with vortioxetine or agomelatine. A safety follow-up will be done approximately 4 weeks after the Completion/Withdrawal Visit.

Reporting Groups
  Description
Vortioxetine 10 mg or 20 mg encapsulated tablets, daily, orally
Agomelatine 25 mg or 50 mg encapsulated tablets, daily, orally

Participant Flow:   Overall Study
    Vortioxetine 10 mg or 20 mg     Agomelatine 25 mg or 50 mg  
STARTED     253 [1]   242 [2]
COMPLETED     200     179  
NOT COMPLETED     53     63  
Adverse Event                 15                 23  
Lack of Efficacy                 11                 17  
Non-compliance with study drug                 2                 0  
Protocol Violation                 5                 7  
Withdrawal of Consent                 14                 12  
Lost to Follow-up                 1                 0  
Administrative or Other Reason(s)                 5                 4  
[1] all-patients-treated set (APTS)
[2] APTS



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.

Age and Gender: All-patients-treated set (APTS) – all patients in the APRS who took at least one dose of investigational medicinal product (IMP).

Study Specific Characteristics: Full-analysis set (FAS) - all patients in the APTS who had a valid baseline assessment and at least one valid post-baseline assessment of the MADRS total score.


Reporting Groups
  Description
Vortioxetine 10 mg or 20 mg encapsulated tablets, daily, orally
Agomelatine 25 mg or 50 mg encapsulated tablets, daily, orally
Total Total of all reporting groups

Baseline Measures
    Vortioxetine 10 mg or 20 mg     Agomelatine 25 mg or 50 mg     Total  
Number of Participants  
[units: participants]
  253     242     495  
Age  
[units: years]
Mean ± Standard Deviation
  47.0  ± 12.4     45.6  ± 12.4     46.3  ± 12.4  
Gender  
[units: participants]
     
Female     195     175     370  
Male     58     67     125  
MADRS: Baseline Total Score [1]
[units: units on a scale]
Mean ± Standard Deviation
  29.1  ± 4.4     28.7  ± 4.0     28.9  ± 4.2  
HAM-A: Baseline Total Score [2]
[units: units on a scale]
Mean ± Standard Deviation
  21.6  ± 6.3     21.4  ± 6.2     21.5  ± 6.2  
CGI-S Baseline Severity Score [3]
[units: units on a scale]
Mean ± Standard Deviation
  4.4  ± 0.6     4.4  ± 0.6     4.4  ± 0.6  
SDS Total Baseline Score [4]
[units: units on a scale]
Mean ± Standard Deviation
  19.2  ± 5.3     19.3  ± 5.2     19.3  ± 5.3  
[1] The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 - 60. The higher the score, the more severe.
[2] The Hamilton Anxiety Rating Scale (HAM-A) consists of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behaviour at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic, and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total score from 0 to 56; higher score indicates greater anxiety.
[3] The Clinical Global Impression - Severity of Illness (CGI-S) is a 7-point scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The investigator should use his/her total clinical experience with this patient population to judge how mentally ill the patient is at the time of rating. Higher score indicates that the patient is more ill.
[4] The Sheehan Disability Scale (SDS) comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired). The higher the score, the more severe.



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Change From Baseline in MADRS Total Score at Week 8   [ Time Frame: Baseline and Week 8 ]

2.  Secondary:   Change From Baseline in MADRS Total Score at Week 12   [ Time Frame: Baseline and Week 12 ]

3.  Secondary:   Change From Baseline in HAM-A Total Score at Week 8   [ Time Frame: Baseline and Week 8 ]

4.  Secondary:   Change From Baseline in HAM-A Total Score at Week 12   [ Time Frame: Baseline and Week 12 ]

5.  Secondary:   Change From Baseline in CGI-S Score at Week 8   [ Time Frame: Baseline and Week 8 ]

6.  Secondary:   Change From Baseline in CGI-S Score at Week 12   [ Time Frame: Baseline and Week 12 ]

7.  Secondary:   Change in Clinical Status Using CGI-I Score at Week 8   [ Time Frame: Week 8 ]

8.  Secondary:   Change in Clinical Status Using CGI-I Score at Week 12   [ Time Frame: Week 12 ]

9.  Secondary:   Proportion of Patients Who Respond at Week 8 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline)   [ Time Frame: Baseline and Week 8 ]

10.  Secondary:   Proportion of Patients Who Respond at Week 12 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline)   [ Time Frame: Baseline and Week 12 ]

11.  Secondary:   Proportion of Patients Who Are in Remission at Week 8 (Remission is Defined as a MADRS Total Score <=10)   [ Time Frame: Week 8 ]

12.  Secondary:   Proportion of Patients Who Are in Remission at Week 12 (Remission is Defined as a MADRS Total Score <=10)   [ Time Frame: Week 12 ]

13.  Secondary:   Change From Baseline in SDS Total Score at Week 8   [ Time Frame: Baseline and Week 8 ]

14.  Secondary:   Change From Baseline in SDS Total Score at Week 12   [ Time Frame: Baseline and Week 12 ]


  Serious Adverse Events


  Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: H. Lundbeck A/S
Organization: H. Lundbeck A/S
phone: +45 36301311
e-mail: LundbeckClinicalTrials@lundbeck.com


No publications provided


Responsible Party: H. Lundbeck A/S
ClinicalTrials.gov Identifier: NCT01488071     History of Changes
Other Study ID Numbers: 14178A, 2011-002362-21
Study First Received: November 29, 2011
Results First Received: December 19, 2013
Last Updated: February 11, 2014
Health Authority: Austria: Austrian Medicines and Medical Devices Agency
Belgium: Federal Agency for Medicinal Products and Health Products
Bulgaria: Bulgarian Drug Agency
Czech Republic: State Institute for Drug Control
Estonia: The State Agency of Medicine
Germany: Federal Institute for Drugs and Medical Devices
Italy: The Italian Medicines Agency
Lithuania: State Medicine Control Agency - Ministry of Health
Poland: National Institute of Medicines
Romania: National Agency for Medicines and Medical Devices
Russia: FSI Scientific Center of Expertise of Medical Application
Spain: Spanish Agency of Medicines
Sweden: Medical Products Agency
United Kingdom: Medicines and Healthcare Products Regulatory Agency